Zhejiang Tianyu Pharmaceutical Co Ltd Asset Resilience Ratio
Zhejiang Tianyu Pharmaceutical Co Ltd asset resilience ratio. Zhejiang Tianyu Pharmaceutical Co Ltd (300702) has an Asset Resilience Ratio of 0.02% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zhejiang Tianyu Pharmaceutical Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zhejiang Tianyu Pharmaceutical Co Ltd (2013–2025)
Asset resilience ratio of Zhejiang Tianyu Pharmaceutical Co Ltd from 2013 to 2025. This chart shows how Zhejiang Tianyu Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Zhejiang Tianyu Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Tianyu Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300702 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.36 Million | 0.02% |
| Total Liquid Assets | CN¥1.36 Million | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Tianyu Pharmaceutical Co Ltd maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Tianyu Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Tianyu Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Zhejiang Tianyu Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2013–2025)
Zhejiang Tianyu Pharmaceutical Co Ltd asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Zhejiang Tianyu Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | CN¥798.90K ≈ $116.90K |
CN¥6.59 Billion ≈ $964.21 Million |
-1.25pp |
| 2021-12-31 | 1.26% | CN¥72.94 Million ≈ $10.67 Million |
CN¥5.80 Billion ≈ $848.81 Million |
+0.48pp |
| 2020-12-31 | 0.78% | CN¥37.91 Million ≈ $5.55 Million |
CN¥4.89 Billion ≈ $715.50 Million |
+0.68pp |
| 2017-12-31 | 0.10% | CN¥2.07 Million ≈ $302.58K |
CN¥2.11 Billion ≈ $308.27 Million |
+0.05pp |
| 2016-12-31 | 0.05% | CN¥727.90K ≈ $106.51K |
CN¥1.52 Billion ≈ $221.70 Million |
-0.17pp |
| 2013-12-31 | 0.21% | CN¥2.07 Million ≈ $303.01K |
CN¥971.79 Million ≈ $142.20 Million |
-- |
About Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-allergic, anticancer, anti-fungal, anti-epileptic, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It also provides fine… Read more